Alphadyne Asset Management LP
Position in REGN — Regeneron Pharmaceuticals, Inc.
CIK 1535943
NEW YORK, NY
Position in REGN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$582,570
+$582,570 QoQ
Shares Held
754
Ownership
0.001%
of shares outstanding
% of Portfolio
0.08%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2023
4 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in REGN Over Time
Shares Held
Position Value (USD)
Derivatives in REGN
reported options exposure · as of Mar 31, 2026CallValue
$4,558,576
CallShares
5,900
PutValue
$5,640,272
PutShares
7,300
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026Alphadyne Asset Management LP holds $5,118,929 across 5 Biotechnology names. REGN ranks #2 (11.4% of the industry book) .
All Filings in REGN
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $5,640,272 | 7,300 | Put | Sole | 2026-05-15 | |
| 2026-03-31 | $4,558,576 | 5,900 | Call | Sole | 2026-05-15 | |
| 2026-03-31 | $582,570 | 754 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $3,473,415 | 4,500 | Put | Sole | 2026-02-17 | |
| 2025-12-31 | $2,855,919 | 3,700 | Call | Sole | 2026-02-17 | |
| 2025-09-30 | $285,633 | 508 | Shares | Sole | 2025-11-14 | |
| 2025-09-30 | $1,855,491 | 3,300 | Put | Sole | 2025-11-14 | |
| 2025-09-30 | $899,632 | 1,600 | Call | Sole | 2025-11-14 | |
| 2023-09-30 | $1,069,848 | 1,300 | Put | Sole | 2023-11-14 | |
| 2023-09-30 | $237,835 | 289 | Shares | Sole | 2023-11-14 | |
| No filing history on record for this holder in this stock. | ||||||